Sorry!! The article you are trying to read is not available now.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
INCYTE RG (NQ: INCY)
62.99 USD  UNCHANGED
Official Closing Price  /  Updated: 8:00 PM EDT, Apr 25, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 3,689,835
Open 62.61
Bid (Size) 62.59 (100)
Ask (Size) 63.80 (100)
Prev. Close 62.99
Today's Range 62.35 - 63.93
52wk Range 61.30 - 140.11
Shares Outstanding 211,798,739
Dividend Yield N/A
Performance
YTD
-37.57%
-37.57%
1 Month
-27.07%
-27.07%
3 Month
-33.93%
-33.93%
6 Month
-45.01%
-45.01%
1 Year
-49.36%
-49.36%
Featured News
More News
Here are Friday’s worst stocks as trade conflict and a weak jobs report disappoint investors
Dow industrials led the market lower, with Caterpillar, Intel and Boeing all down more than 3%. Read More
category GE , DJIA , MCD , and 65 more.
from MarketWatch
As stocks recover, Goldman sees ‘lowered bar’ for volatility’s return
The U.S. stock market has largely recovered since the correction it suffered in early February, but those gains could mean investors are failing to appreciate the potential for volatility returning to... Read More
category COMP , GE , INCY , and 11 more.
from MarketWatch
Featured News
Read More
In the bull market’s ninth year, ‘winning’ stocks hide lingering pain
category XOM , SPX , REGN , and 73 more.
from MarketWatch
Five biotech buyout candidates you should look at right now
category MRUS , XBI , Opinion , and 15 more.
from MarketWatch
Biggest Nasdaq winners and losers in 2017: Chip makers, videogame publishers lead tech
category ORLY , ATVI , TTWO , and 40 more.
from MarketWatch
Why 2018 is a make-or-break year for pharma
category NBIX , General , CELG , and 17 more.
from MarketWatch
Analysts expect these large-cap U.S. stocks to rise at least 25% in 2018
category ATVI , FB , MYL , and 48 more.
from MarketWatch
Six promising stocks to buy when the biotech correction ends
category AZN , ALXN , LLY , and 22 more.
from MarketWatch
More News
Read More
FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
from PR Newswire
Incyte Highlights Abstracts Accepted for Presentation at the 2018 ASCO Annual Meeting
from Business Wire News Releases
Syros Takes The Road Less Traveled In Gene Control, Awaits Windfall From Diverse Indications
category Benzinga , Top Stories , General , and 6 more.
from Benzinga
Nasdaq 100 Movers: INCY, CDNS
category Stocks
from Market News Video
Lessons to Learn From April's Biotech Blowups
category MRK , CLDX , PRTA , and 1 more.
from Motley Fool
Is Eli Lilly and Company a Buy?
category LLY , INCY
from Motley Fool
Eli Lilly shares slip despite earnings beat
category Health care industry , Eli Lilly and Co , Medical biotechnology industry , and 5 more.
from CNBC.com News
UPDATE 2-FDA panel against higher dose of Lilly-Incyte arthritis drug
category companyNews
from Reuters: Company News
Morning Call For Tuesday, April 24
category Currencies/Forex , Bonds , Commodities , and 2 more.
from Blogs - TalkMarkets
UPDATE 1-FDA panel backs lower dose of Lilly-Incyte arthritis drug over higher
category companyNews
from Reuters: Company News
FDA panel votes against approving higher dose of Lilly-Incyte arthritis drug
category companyNews
from Reuters: Company News
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial

WHAT'S POPULAR IN THE VILLE